Literature DB >> 28992315

Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis.

Wendy Kloezen1, Florianne Parel1, Roger Brüggemann2, Khalid Asouit2, Marilyn Helvert-van Poppel3, Ahmed Fahal4, Johan Mouton1, Wendy van de Sande1.   

Abstract

Mycetoma is a tropical neglected disease characterized by large subcutaneous lesions in which the causative organisms reside in the form of grains. The most common causative agent is Madurella mycetomatis. Antifungal therapy often fails due to these grains, but to identify novel treatment options has been difficult since grains do not form in vitro. We recently used Galleria mellonella larvae to develop an in vivo grain model. In the current study, we set out to determine the therapeutic efficacy of commonly used antifungal agents in this larval model. Pharmacokinetics of ketoconazole, itraconazole, voriconazole, posaconazole, amphotericin B, and terbinafine were determined in the hemolymph of G. mellonella larvae. Antifungal therapy was given either therapeutically or prophylactic on three consecutive days in therapeutically equivalent dosages. Survival was monitored for 10 days and colony-forming units (cfu) and melanization were determined on day 3. Measurable concentrations of antifungal agents were found in the hemolymph of the larvae. None of the azole antifungal agents prolonged survival when given therapeutically or prophylactically. Amphotericin B and terbinafine did prolong survival, even at concentrations below the minimal inhibitory concentration of M. mycetomatis. The cfu and melanization did not differ between any of the treated groups and phosphate-buffered saline (PBS) treated groups. Grains were still present in surviving larvae but appeared to be encapsulated. This study demonstrated for the first time a comparison between the efficacy of different antifungal agents toward grains of M. mycetomatis. It appeared that amphotericin B and terbinafine were able to prolong larval survival.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28992315     DOI: 10.1093/mmy/myx064

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  10 in total

Review 1.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

2.  Efficacy of Antifungal Monotherapies and Combinations against Aspergillus calidoustus.

Authors:  E Glampedakis; A T Coste; M Aruanno; D Bachmann; E Delarze; V Erard; F Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

3.  In vitro susceptibility testing for black grain eumycetoma causative agents.

Authors:  Wendy W J van de Sande
Journal:  Trans R Soc Trop Med Hyg       Date:  2021-04-14       Impact factor: 2.184

4.  The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma.

Authors:  Mickey Konings; Kimberly Eadie; Wilson Lim; Ahmed H Fahal; Johan Mouton; Nicolas Tesse; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2021-06-09

Review 5.  The Use of Galleria mellonella Larvae to Identify Novel Antimicrobial Agents against Fungal Species of Medical Interest.

Authors:  Kevin Kavanagh; Gerard Sheehan
Journal:  J Fungi (Basel)       Date:  2018-09-19

Review 6.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Authors:  Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen
Journal:  Microb Cell       Date:  2018-06-14

Review 7.  Galleria mellonella for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review.

Authors:  Sana Jemel; Jacques Guillot; Kalthoum Kallel; Françoise Botterel; Eric Dannaoui
Journal:  Microorganisms       Date:  2020-03-11

8.  Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.

Authors:  Wilson Lim; Bertrand Nyuykonge; Kimberly Eadie; Mickey Konings; Juli Smeets; Ahmed Fahal; Alexandro Bonifaz; Matthew Todd; Benjamin Perry; Kirandeep Samby; Jeremy Burrows; Annelies Verbon; Wendy van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2022-02-04

9.  Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma.

Authors:  Wilson Lim; Youri Melse; Mickey Konings; Hung Phat Duong; Kimberly Eadie; Benoît Laleu; Benjamin Perry; Matthew H Todd; Jean-Robert Ioset; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2018-04-26

10.  Proteomic analysis of the processes leading to Madurella mycetomatis grain formation in Galleria mellonella larvae.

Authors:  Gerard Sheehan; Mickey Konings; Wilson Lim; Ahmed Fahal; Kevin Kavanagh; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2020-04-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.